利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.021 秒)

    SOLID DELIVERY COMPOSITION
    1.
    发明申请
    SOLID DELIVERY COMPOSITION 有权

    公开(公告)号：US20210007993A1

    公开(公告)日：2021-01-14

    申请号：US16956956

    申请日：2018-12-20

    申请人： COSMO TECHNOLOGIES LTD.

    发明人： Luigi Maria LONGO ,  Cristina MACELLONI ,  Silvia ROSSI ,  Franca FERRARI

    IPC分类号： A61K9/20 ,  A61K38/19 ,  A61K9/48 ,  A61K9/16

    摘要： The present invention provides an innovative combination of biomaterials, multifunctional polymers, able to structure themselves at the site of action. The innovative combination of biomaterials of the invention is formulated in a solid composition and can be used as a versatile delivery vehicle or carrier in many pharmaceutical fields. The solid composition comprising the combination of biomaterials of the invention is provided to target delivery for medical purposes in humans.

    ORAL RIFAMYCIN SV COMPOSITIONS
    2.
    发明申请
    ORAL RIFAMYCIN SV COMPOSITIONS 有权

    公开(公告)号：US20230135346A1

    公开(公告)日：2023-05-04

    申请号：US18146510

    申请日：2022-12-27

    申请人： COSMO TECHNOLOGIES LTD.

    发明人： Luigi MORO ,  Luigi Maria LONGO

    IPC分类号： A61K9/00 ,  A61P1/12 ,  A61K9/28 ,  A61K31/395

    摘要： Oral pharmaceutical compositions containing rifamycin SV, or a pharmaceutically salt thereof, characterized in that they are formulated in a higher strength (about 600 mg/tablet) and in such a manner to obtain a modified profile of the rifamycin SV, or a pharmaceutically acceptable salt thereof, in the proximal portion of the intestine, i.e. in the small intestine (duodenum, jejunum and ileum). In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment in a subject of small intestine bacterial overgrowth (SIBO) and/or irritable bowel syndrome (IBS) and/or in the treatment of cholera. In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment in a subject of hepatic encephalopathy, hepatic cirrhosis, pouchitis and/or spontaneous bacterial perotinitis. In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment in a subject of non-alcoholic fatty liver disease, non-alcoholic fatty liver or non-alcoholic steatohepatitis.

    ORAL RIF AMYCIN SV COMPOSITIONS
    3.
    发明申请
    ORAL RIF AMYCIN SV COMPOSITIONS 审中-公开

    公开(公告)号：US20200281850A1

    公开(公告)日：2020-09-10

    申请号：US16762760

    申请日：2018-11-07

    申请人： COSMO TECHNOLOGIES LTD.

    发明人： Luigi MORO ,  Luigi Maria LONGO

    IPC分类号： A61K9/00 ,  A61K31/395 ,  A61K9/28 ,  A61P1/12

    摘要： Oral pharmaceutical compositions containing rifamycin SV, or a pharmaceutically salt thereof, characterized in that they are formulated in a higher strength (about 600 mg/tablet) and in such a manner to obtain a modified profile of the rifamycin SV, or a pharmaceutically acceptable salt thereof, in the proximal portion of the intestine, i.e. in the small intestine (duodenum, jejunum and ileum). In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment in a subject of small intestine bacterial overgrowth (SIBO) and/or irritable bowel syndrome (IBS) and/or in the treatment of cholera. In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment in a subject of hepatic encephalopathy, hepatic cirrhosis, pouchitis and/or spontaneous bacterial perotinitis. In one embodiment, the disclosed oral pharmaceutical compositions are used in the prevention and/or treatment in a subject of non-alcoholic fatty liver disease, non-alcoholic fatty liver or non-alcoholic steatohepatitis.